Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.60 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16402314 | 1.00 | SIGMAR1 (0.60) | SIGMAR1TMEM97KMT2AACHEDRD4 | |
| SCHEMBL18100722 | 1.00 | SIGMAR1 (0.60) | SIGMAR1TMEM97KMT2AACHEDRD4 | |
| SCHEMBL18099297 | 1.00 | SIGMAR1 (0.60) | SIGMAR1TMEM97KMT2AACHEDRD4 | |
| SCHEMBL21871140 | 1.00 | SIGMAR1 (0.60) | SIGMAR1TMEM97KMT2AACHEDRD4 | |
| SCHEMBL16408564 | 1.00 | SIGMAR1 (0.60) | SIGMAR1TMEM97KMT2AACHEDRD4 | |
| SCHEMBL18099332 | 0.94 | SIGMAR1 (0.55) | SIGMAR1TMEM97KMT2ACHRM3 | |
| SCHEMBL18100571 | 0.94 | SIGMAR1 (0.55) | SIGMAR1TMEM97KMT2ACHRM3 | |
| SCHEMBL16408535 | 0.94 | SIGMAR1 (0.55) | SIGMAR1TMEM97KMT2ACHRM3 | |
| SCHEMBL16408637 | 0.94 | SIGMAR1 (0.55) | SIGMAR1TMEM97KMT2ACHRM3 | |
| SCHEMBL18099328 | 0.86 | SIGMAR1 (0.52) | SIGMAR1TMEM97ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115345-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, NEUROLOGICAL DISORDERS, ETHANOL WITHDRAWAL, ANXIETY, DEPRESSION, AND NEUROPATHIC PAIN | UNIV TEXAS (US) | 2020-04-16 | — | — | US | disclosed |
| US-10450275-B2 | Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-10-22 | — | — | US | disclosed |
| US-20160280657-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, NEUROLOGICAL DISORDERS, ETHANOL WITHDRAWAL, ANXIETY, DEPRESSION, AND NEUROPATHIC PAIN | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2016-09-29 | — | — | US | disclosed |
| US-20160280657-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, NEUROLOGICAL DISORDERS, ETHANOL WITHDRAWAL, ANXIETY, DEPRESSION, AND NEUROPATHIC PAIN | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2016-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115345-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, NEUROLOGICAL DISORDERS, ETHANOL WITHDRAWAL, ANXIETY, DEPRESSION, AND NEUROPATHIC PAIN | ELAVL1, ADH1A, NGF | SIGMAR1 423/4885TMEM97 1532/4885KMT2A 812/4885 |
| US-20160280657-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER, NEUROLOGICAL DISORDERS, ETHANOL WITHDRAWAL, ANXIETY, DEPRESSION, AND NEUROPATHIC PAIN | ELAVL1, ADH1A, NGF | SIGMAR1 423/4885TMEM97 1532/4885KMT2A 812/4885 |
| US-10450275-B2 | Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain | ELAVL1, ADH1A, NGF | SIGMAR1 423/4885TMEM97 1532/4885KMT2A 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.